Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Plain-language summary
This trial is testing Cyclophosphamide for patients with adult T-cell leukemia/lymphoma (ATLL) or cutaneous T-cell lymphoma (CTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. This trial is available at 1 location in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Cyclophosphamide (DRUG): Given IV | Fludarabine (DRUG): Given IV | Mogamulizumab (BIOLOGICAL): Given IV | Natural Killer Cell Therapy (BIOLOGICAL): Given via infusion | Quality-of-Life Assessment (OTHER): Ancillary studies | Questionnaire Administration (OTHER): Ancillary studies
Cyclophosphamide, Fludarabine, Mogamulizumab, Natural Killer Cell Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details